ADCT NYSE
ADC Therapeutics S.A.
1W: +4.6%
1M: +26.2%
3M: +44.5%
YTD: -54.8%
1Y: -61.1%
3Y: +91.6%
5Y: -93.8%
$1.59
+0.08 (+5.30%)
Weekly Expected Move ±17.5%
$1
$1
$1
$2
$2
Credit Risk of going bust: higher than 95% of companies Debt: 67.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.46 (down 71%), ADC Therapeutics S.A. would be worth roughly what it owes.
Total debt $417.1M against a stock market value of $203.0M.
Distance to default 0.64 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $211.6M (short-term plus half of long-term), stock volatility 116.6%; Altman Z'' -18.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $417.1M against a stock market value of $203.0M.
Distance to default 0.64 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $211.6M (short-term plus half of long-term), stock volatility 116.6%; Altman Z'' -18.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$79M
Revenue
+2.0% YoY
$-97M
Net Income
+43.0% YoY
$-102M
Free Cash Flow
+20.0% YoY
87.8%
Gross Margin
-132.0%
Op. Margin
-86.1%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE45.3%
ROA-32.3%
ROIC260.9%
Valuation
P/E-2.4
P/B-1.1
EV/EBITDA-4.2
Leverage
Debt/Equity-1.83
Current Ratio3.03
Interest Cov.-1.7x
Quality Scores
Piotroski F2/9
Altman Z-8.25
Beneish M3.09